技术指标
指标
数值
方向
MACD(12,26,9)
-0.008
卖出
RSI(14)
40.107
中性
STOCH(KDJ)(9,3,3)
39.051
中性
ATR(14)
0.052
低波动
CCI(14)
-66.111
中性
Williams %R
72.054
卖出
TRIX(12,20)
-0.754
卖出
StochRSI(14)
48.639
卖出
搜索
Mustang Bio Inc
MBIO添加自选
0.570USD
-0.024-3.97%
收盘 07-31 16:00（美东）报价延迟15分钟
4.32M总市值
亏损市盈率 TTM
关键数据
0.597今开
0.618最高
11.07K成交量
亏损市盈率 TTM
--市盈率动
--股息TTM
0.15%换手率
0.594昨收
0.560最低
4.43K成交额
亏损市盈率静
0.50市净率
0.00%股息率 TTM
-17.29%ROA
7.00052周最高
0.28量比
-15.75M净利润
7.58M总股本
-0.4798每股收益TTM
2.08Beta
-44.62%ROE
0.53152周最低
9.73%振幅
--毛利率
4.32M总市值
-3.12回报/风险
4.97%风险率
TradingKey Mustang Bio Inc股票评分
单位: USD 更新时间: 2026-07-31操作建议
Mustang Bio Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名196/385位。机构持股占比非常高，中期看，股价处于下降通道。近一个月，市场表现非常差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Mustang Bio Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Mustang Bio Inc亮点
亮点风险
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs into potential cures for cancers and autoimmune diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR T) therapies. Its pipeline is focused in two core areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors. It is developing a CAR T therapy for hematologic malignancies and autoimmune diseases in partnership with Fred Hutchinson Cancer Center targeting CD20 and for solid tumors in partnership with City of Hope National Medical Center targeting IL13Ra2. It has also partnered with Nationwide Children’s Hospital for a herpes simplex virus type 1 oncolytic virus to enhance the activity of MB-101 for the treatment of patients with high-grade malignant brain tumors.
估值低估
公司最新PE估值-1.19，处于3年历史低位
机构加仓
最新机构持股664.20K股，环比增加22.79%
分析师目标
根据
0
位分析师
--
评级
--
目标均价
--
涨幅空间
Mustang Bio Inc新闻
即将为您带来更多新闻，敬请期待。。。
技术指标
移动平均线
指标
数值
方向
MA5
0.587
卖出
MA10
0.593
卖出
MA20
0.635
卖出
MA50
0.671
卖出
MA100
0.717
卖出
MA200
0.927
卖出
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Mustang Bio Inc简介
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs into potential cures for cancers and autoimmune diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR T) therapies. Its pipeline is focused in two core areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors. It is developing a CAR T therapy for hematologic malignancies and autoimmune diseases in partnership with Fred Hutchinson Cancer Center targeting CD20 and for solid tumors in partnership with City of Hope National Medical Center targeting IL13Ra2. It has also partnered with Nationwide Children’s Hospital for a herpes simplex virus type 1 oncolytic virus to enhance the activity of MB-101 for the treatment of patients with high-grade malignant brain tumors.
公司代码MBIO
公司Mustang Bio Inc
CEOLitchman (Manuel)
网址https://www.mustangbio.com/
公司股东
相关品种
热门品种
常见问题
Mustang Bio Inc(MBIO)的当前股价是多少？
Mustang Bio Inc(MBIO)的当前股价是 0.57。
Mustang Bio Inc的股票代码是什么？
Mustang Bio Inc的股票代码是MBIO。
Mustang Bio Inc股票的52周最高点是多少？
Mustang Bio Inc股票的52周最高点是7.00。
Mustang Bio Inc股票的52周最低点是多少？
Mustang Bio Inc股票的52周最低点是0.53。
Mustang Bio Inc的市值是多少？
Mustang Bio Inc的市值是4.32M。
Mustang Bio Inc(MBIO)股票的每股收益（EPS TTM）是多少
Mustang Bio Inc(MBIO)股票的每股收益（EPS TTM）是-0.39。